FIGURES

(a)



HA-EGCG (A)

(b)



HA-EGCG (B)

(c)



HA-EGCG (C)

FIG. 1



FIG. 2



FIG. 3



FIG. 4



FIG. 5



FIG. 6



FIG. 7


(a)
Peripheral blood
Control
Free sora
Sora-MNC
n.s.
*
% human CD45
Time (weeks)
(b)
Peripheral blood
Control (n = 3)
Free sorafenib (n = 5)
Sora-NP-1 (n = 8)
% human CD45
Week 0
Week 1
Week 2
Week 3
Week 4

FIG. 8


(a)
Spleen
Bone marrow
% human CD45
100
80
60
40
20
0
Control
Free sorafenib
Sora-NP-1
(b)
Spleen
Bone marrow
***
**
n.s.
n.s.
% human CD45
Control
Free sorafenib
Sora-NP-1

FIG. 9


Survival probability (%)
100
80
60
40
20
0
0
5
10
15
20
25
30
Days
Treatment period
***
**
Control (n = 7)
Free sorafenib (n = 8)
Sora-NP-1 (n = 11)

FIG. 10


40
40
42
46
48
44
46
50
52

FIG. 11


a)
HL60
Counts
Negative control
Isotype control
CD44
Fluorescence Intensity
b)
NB4
Counts
Negative control
Isotype control
CD44
Fluorescence Intensity

FIG. 12


(a)
HL60
Cell Viability (%)
48 h 72 h
HA
EGCG
HA + EGCG
HA-EGCG (A)
HA-EGCG (B)
(b)
NB4
Cell Viability (%)
48 h 72 h
HA
EGCG
HA + EGCG
HA-EGCG (A)
HA-EGCG (B)

FIG. 13


(a)
HL60
NB4
HEK293
HUVEC
Cell viability (%)
EGCG (μM)
EGCG
HA-EGCG (A)
HA-EGCG (B)
(b)
HA-EGCG (500 μg/ml)
Cell Viability (%)
HL60
NB4
HEK293
HUVEC
AML cells
Normal cells

FIG. 14


(a)
Fold Change Relative to Control
5.0
3.0
1.5
1.0
0.5
0.0
CD11b
CD14
CD15
HA
EGCG
HA-EGCG (A)
HA-EGCG (B)
PMA
ATRA
A3D8
(b)
Marker-expressing Cells (%)
40
30
20
8
6
4
2
0
CD11b
CD14
CD15
HA
EGCG
HA-EGCG (A)
HA-EGCG (B)
PMA
ATRA
A3D8

FIG. 15


(a)
Fold Change Relative to Control
2.0
1.5
1.0
0.5
0.0
CD11b
CD14
CD15
HA
EGCG
HA-EGCG (A)
HA-EGCG (B)
PMA
ATRA
A3D8
(b)
Marker-expressing Cells (%)
20
10
6
5
4
3
2
1
0
CD11b
CD14
CD15
HA
EGCG
HA-EGCG (A)
HA-EGCG (B)
PMA
ATRA
A3D8

FIG. 16



FIG. 17


Control
HA-EGCG (B)
Red Blood Cells (x10⁶/μL)
16
14
12
10
8
6
4
2
0
28
35
43
49
Day after inoculation

FIG. 18


(a)
Control
HA-EGCG (B)
White Blood Cells (x1000/μL)
***
Day after inoculation
(b)
Control
HA-EGCG (B)
Body Weight (%)
Days after inoculation
(c)
Control
HA-EGCG (B)
Survival Fraction
**
Days after inoculation
(d)
Spleen Weight (%)
*
Control
HA-EGCG (B)

FIG. 19